Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Liafensine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 20/20 | 1.00 |
| ▸ | SLC6A3 known ✓ | Q01959 | 20/20 | 1.00 |
| ▸ | SLC6A4 known ✓ | P31645 | 19/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Liafensine SCHEMBL12573238 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A3SLC6A4 | |
| Liafensine SCHEMBL1120125 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A3SLC6A4 | |
| Liafensine SCHEMBL29376965 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A3SLC6A4 | |
| Liafensine SCHEMBL1119993 | 0.99 | SLC6A2 (0.98) | SLC6A2SLC6A3SLC6A4 | |
| Liafensine SCHEMBL1119990 | 0.99 | SLC6A2 (0.98) | SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL1248803 | 0.90 | SLC6A2 (0.81) | SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL17461972 | 0.90 | SLC6A2 (0.81) | SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL4306960 | 0.90 | SLC6A2 (0.81) | SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL1503336 | 0.89 | SLC6A2 (0.80) | SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL1503335 | 0.89 | SLC6A2 (0.80) | SLC6A2SLC6A3SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230193388-A1 | COMPOSITIONS AND METHODS FOR ASSESSING THE EFFICACY OF INHIBITORS OF NEUROTRANMITTER TRANSPORTERS | DENOVO BIOPHARMA LLC (US) | 2023-06-22 | — | — | US | disclosed |
| US-20230193388-A1 | COMPOSITIONS AND METHODS FOR ASSESSING THE EFFICACY OF INHIBITORS OF NEUROTRANMITTER TRANSPORTERS | DENOVO BIOPHARMA LLC (US) | 2023-06-22 | — | — | US | disclosed |
| EP-2280955-B8 | CRYSTALLINE FORM OF 6-[(4S)-2-METHYL-4-(2-NAPHTHYL)-1,2,3,4-TETRAHYDROISOQUINOLIN-7-YL]PYRIDAZIN-3-AMINE | ALBANY MOLECULAR RES INC (US) | 2017-12-27 | — | — | EP | disclosed |
| EP-2280955-B1 | CRYSTALLINE FORM OF 6-Ý(4S)-2-METHYL-4-(2-NAPHTHYL)-1,2,3,4-TETRAHYDROISOQUINOLIN-7-YL¨PYRIDAZIN-3-AMINE | ALBANY MOLECULAR RES INC (US) | 2017-10-18 | — | — | EP | disclosed |
| EP-2280955-B1 | CRYSTALLINE FORM OF 6-Ý(4S)-2-METHYL-4-(2-NAPHTHYL)-1,2,3,4-TETRAHYDROISOQUINOLIN-7-YL¨PYRIDAZIN-3-AMINE | ALBANY MOLECULAR RES INC (US) | 2017-10-18 | — | — | EP | disclosed |
| EP-2280955-B1 | CRYSTALLINE FORM OF 6-Ý(4S)-2-METHYL-4-(2-NAPHTHYL)-1,2,3,4-TETRAHYDROISOQUINOLIN-7-YL¨PYRIDAZIN-3-AMINE | ALBANY MOLECULAR RES INC (US) | 2017-10-18 | — | — | EP | disclosed |
| US-9498476-B2 | Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine | ALBANY MOLECULAR RESEARCH, INC. (US) | 2016-11-22 | — | — | US | disclosed |
| US-9498476-B2 | Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine | ALBANY MOLECULAR RESEARCH, INC. (US) | 2016-11-22 | — | — | US | disclosed |
| US-9498476-B2 | Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine | ALBANY MOLECULAR RESEARCH, INC. (US) | 2016-11-22 | — | — | US | disclosed |
| US-9498476-B2 | Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine | ALBANY MOLECULAR RESEARCH, INC. (US) | 2016-11-22 | — | — | US | disclosed |
| EP-2280956-A2 | PROCESSES FOR PREPARING TETRAHYDROISOQUINOLINES | Bristol-Myers Squibb Company (US) | 2011-02-09 | — | — | EP | disclosed |
| EP-2280956-A2 | PROCESSES FOR PREPARING TETRAHYDROISOQUINOLINES | Bristol-Myers Squibb Company (US) | 2011-02-09 | — | — | EP | disclosed |
| WO-2009149259-A3 | PROCESSES FOR PREPARING TETRAHYDROISOQUINOLINES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-04-15 | — | — | WO | disclosed |
| WO-2009149258-A3 | CRYSTALLINE FORM OF 6-[(4S)-2-METHYL-4-(2-NAPHTHYL)-1,2,3,4-TETRAHYDROISOQUINOLIN-7-YL]PYRIDAZIN-3-AMINE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-02-04 | — | — | WO | disclosed |
| WO-2009149258-A2 | CRYSTALLINE FORM OF 6-[(4S)-2-METHYL-4-(2-NAPHTHYL)-1,2,3,4-TETRAHYDROISOQUINOLIN-7-YL]PYRIDAZIN-3-AMINE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-12-10 | — | — | WO | disclosed |
| WO-2009149258-A2 | CRYSTALLINE FORM OF 6-[(4S)-2-METHYL-4-(2-NAPHTHYL)-1,2,3,4-TETRAHYDROISOQUINOLIN-7-YL]PYRIDAZIN-3-AMINE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-12-10 | — | — | WO | disclosed |
| WO-2009149258-A2 | CRYSTALLINE FORM OF 6-[(4S)-2-METHYL-4-(2-NAPHTHYL)-1,2,3,4-TETRAHYDROISOQUINOLIN-7-YL]PYRIDAZIN-3-AMINE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-12-10 | — | — | WO | disclosed |
| WO-2009149259-A2 | PROCESSES FOR PREPARING TETRAHYDROISOQUINOLINES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-12-10 | — | — | WO | disclosed |
| WO-2009149259-A2 | PROCESSES FOR PREPARING TETRAHYDROISOQUINOLINES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-12-10 | — | — | WO | disclosed |
| WO-2009149259-A2 | PROCESSES FOR PREPARING TETRAHYDROISOQUINOLINES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-12-10 | — | — | WO | disclosed |